Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Daniela Renkiewicz

Internal Medicine Battle Creek, MI Medical Doctor

NPI 1790783793 CMS profile 127006

2845 Capital Ave Sw, Suite 302, Battle Creek, MI 49015

Open in the dashboard

General payments

$9,019

545 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Daniela Renkiewicz of Battle Creek, MI is reported in the CMS Open Payments database as having received $9,019 across 545 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,595 88
2023 General $2,140 118
2022 General $1,350 81
2021 General $1,122 64
2020 General $1,220 74
2019 General $1,593 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniela Renkiewicz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Daniela Renkiewicz were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Daniela Renkiewicz Internal Medicine median Middle half National median
2019 $1,593 $159 $48–$570 $163
2020 $1,220 $119 $33–$402 $114
2021 $1,122 $135 $37–$521 $132
2022 $1,350 $141 $42–$496 $149
2023 $2,140 $149 $45–$519 $160
2024 $1,595 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $1,464 88 payments
  2. Xeris Pharmaceuticals, Inc. $765 42 payments
  3. Pfizer Inc. $658 48 payments
  4. AbbVie, Inc. $633 50 payments
  5. Amgen Inc. $632 37 payments
  6. Amarin Pharma Inc. $512 37 payments
  7. AstraZeneca Pharmaceuticals LP $403 15 payments
  8. Merck Sharp & Dohme Corporation $351 19 payments
  9. Lilly USA, LLC $336 25 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $271 14 payments
  11. Other $2,994 170 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $8,958 536 payments
  2. Education $61 9 payments
Products named General payments · program years 2019–2024
  1. Ozempic $1,142 68 payments
  2. RYBELSUS $870 53 payments
  3. GVOKE PFS $532 29 payments
  4. NURTEC ODT Pain $468 23 payments
  5. Vascepa $396 25 payments
  6. NURTEC ODT Primary Care $349 14 payments
  7. HUMIRA $348 30 payments
  8. FARXIGA $338 10 payments
  9. PAXLOVID $258 15 payments
  10. Prolia $237 14 payments
  11. Other $7,502 479 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

5,918

Median for Internal Medicine: 777

Drug cost

$427,486

Median for Internal Medicine: $73,373

Branded share of claims

15.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 54 $73,316
Rybelsus Semaglutide Brand 34 $59,159
Eliquis Apixaban Brand 41 $39,157
Mounjaro Tirzepatide Brand 33 $38,434
Ozempic Semaglutide Brand 19 $29,494
Myrbetriq Mirabegron Brand 15 $20,080
Farxiga Dapagliflozin Propanediol Brand 18 $18,661
Xarelto Rivaroxaban Brand 13 $18,561
Januvia Sitagliptin Phosphate Brand 15 $15,671
Trulicity Dulaglutide Brand 12 $11,148

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$50,752

Medicare's payments for the services billed

Medicare patients

346

Average age 76

Services billed

756

255 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Chronic kidney disease 41%
Depression 30%
Diabetes 27%
Osteoporosis 23%
Ischemic heart disease 16%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $150
$150 19 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $118
$118 18 —
REXULTI
  • Lundbeck LLC $92
  • Otsuka America Pharmaceutical, Inc. $25
$117 — —
NURTEC ODT
  • PFIZER INC. $88
$88 — —
RYBELSUS
  • Novo Nordisk Inc $84
$84 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

545 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record